Business
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 trial, utilising OXB lentiviral vectors; builds on long term collaboration with Boehringer Ingelheim Oxford, UK – 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be use
About this update from Oxford Biomedica Plc
[{"type":"image","alt":"OXB","displaySize":"","headline":null,"caption":"OXB","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fa8vdAQ1u36jC9pq9QpcgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2","width":300,"height":159}},"lazy":false},{"type":"text","content":"OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"Commencement of LENTICLAIR™ 1 trial, utilising OXB lentiviral vectors; builds on long term collaboration with Boehringer Ingelheim","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"Oxford, UK – 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim's newly initiated LENTICLAIR™ 1 trial. The Phase I/II study is evaluating BI 3720931, a novel, first-in-class, inhaled gene therapy for the treatment of cystic fibrosis (CF).","length":411,"tagName":"p"},{"type":"text","content":"With three decades of expertise in viral vector development and manufacturing, OXB will support the development of this potential treatment for CF, a genetic condition caused by mutations in the CFTR gene that affects more than 100,000 people worldwide. While CFTR modulators have provided treatment options for some patients, there remains a significant unmet need for 10-15% of people with CF due to mutation type or modulator intolerance.","length":441,"tagName":"p"},{"type":"text","content":"BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy designed to address this need through a novel approach of inserting a functional copy of the CFTR gene in the DNA of airway epithelial cells.","length":218,"tagName":"p"},{"type":"text","content":"This trial builds on the successful collaboration initiated in August 2018 with Boehringer Ingelheim. OXB’s ongoing role in this programme highlights its reputation as a trusted CDMO and its commitmen...